Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT04602338
Recruiting Observational

Diagnosis and OutcoMes evaluAtIoN of Multicenter Patients With HFpEF Using Multimodality Imaging

NCT04602338 · tracked via the Priya Life Science China tracker
Sponsor
Chinese Academy of Medical Sciences, Fuwai Hospital
Phase
Observational
Started
2020-11-01
Last updated
2022-04-18

Condition(s) studied

Heart Failure, DiastolicMulticenter Study

Study summary

The incidence of Heart failure with preserved ejection fraction (HFpEF) in Heart failure patients increases rapidly. However, the current clinical awareness is insufficient, and the cardiac structural and functional injury are not well understood. It is difficult to recognize the subclinical changes of the cardiac in the early stage with conventional imaging techniques, and it is common to ignore the existence of the clinical alterations. This study aimed to investigate the cardiac features, early diagnosis and risk factors of HFpEF patients, based on the multi-modality (Magnetic resonance imaging- nuclear medicine imaging- echocardiography) imaging and multicenter study, combined with large data and artificial intelligence. This study will provide deep insights into the HFpEF in multicenter population.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * left ventricular ejection fraction (LVEF)≥50%； * N-terminal pro-b type natriuretic peptide (NT-proBNP)\>220pg/ml or b type natriuretic peptide (BNP) \>80 pg/ml; * symptoms and syndromes of heart failure; * At least one criteria of cardiac structure (left ventricular hypertrophy, or left atrial enlargement) and function abnormalities (based on tissue doppler, color doppler). Exclusion Criteria: * Special types of cardiomyopathy, including hypertrophic cardiomyopathy, restricted cardiomyopathy, etc. * Infarction, myocardial fibrosis caused by ischemic cardiomyopathy and acute coronary syndrome ; * Severe arrhythmia; * Severe primary cardiac valvular disease; * Restrictive pericardial disease; * Refuse to participate in the study.

Primary outcome measure(s)

  • All-cause Death — 1-8 year
    the incidence of all-cause death
  • Cardiovascular Death — 1-8 year
    the incidence of cadridovascular death
  • Hospitalization Due to Heart Failure — 1-8 year
    the incidence of Hospitalization Due to Heart Failure

Trial sites (1)

FacilityCityRegionStatus
Fuwai Hospital Beijing Beijing Municipality Recruiting

More Chinese Academy of Medical Sciences, Fuwai Hospital trials in China

Cardiac Magnetic Resonance for Risk Stratification in Dilated Cardiomyopathy Recruiting
Time to Ambulation After ProGlide Closure Recruiting
Perioperative Dezocine Administration and Postoperative Delirium in Elderly Cardiac Surgery Patients Starting soon
31P-MRS Myocardial Energetic Phenotyping and Prognosis Across the Cardiac Disease Spectrum Recruiting
Cardiac Normal Values Assessed by Magnetic Resonance Imaging Recruiting

Other trials for the same condition

Multi-Omics Inflammatory Phenotype for ABPA Recurrence Risk Prediction Recruiting
Multimodality Imaging in the Screening, Diagnosis and Risk StratifictiON of HFpEF Recruiting
Multicenter Clinical Trial on the Effectiveness and Safety of Instillation of BCG and Alternative BCG Protocols for Intermediate and High-risk Non-muscle Invasive Bladder Cancer Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04602338 on ClinicalTrials.gov ↗ ← All trials in China